Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 147

1.

Public health and economic impact of 13-valent pneumococcal conjugate vaccine in US adults aged ≥50 years.

Weycker D, Sato R, Strutton D, Edelsberg J, Atwood M, Jackson LA.

Vaccine. 2012 Aug 3;30(36):5437-44. doi: 10.1016/j.vaccine.2012.05.076.

PMID:
22728289
2.

Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the United States.

Rubin JL, McGarry LJ, Strutton DR, Klugman KP, Pelton SI, Gilmore KE, Weinstein MC.

Vaccine. 2010 Nov 10;28(48):7634-43. doi: 10.1016/j.vaccine.2010.09.049.

PMID:
20883739
3.
4.

Cost-effectiveness of a 10- versus 13-valent pneumococcal conjugate vaccine in Denmark and Sweden.

Klok RM, Lindkvist RM, Ekelund M, Farkouh RA, Strutton DR.

Clin Ther. 2013 Feb;35(2):119-34. doi: 10.1016/j.clinthera.2012.12.006.

PMID:
23312274
5.

Cost-effectiveness of 13-valent pneumococcal conjugate vaccine: Germany, Greece, and The Netherlands.

Strutton DR, Farkouh RA, Earnshaw SR, Hwang S, Theidel U, Kontodimas S, Klok R, Papanicolaou S.

J Infect. 2012 Jan;64(1):54-67. doi: 10.1016/j.jinf.2011.10.015.

PMID:
22085813
6.

A public health and budget impact analysis of vaccinating at-risk adults and the elderly against pneumococcal diseases in Germany.

Jiang Y, Gauthier A, Annemans L, van der Linden M, Nicolas-Spony L, Bresse X.

Expert Rev Pharmacoecon Outcomes Res. 2012 Oct;12(5):631-43. doi: 10.1586/erp.12.55.

PMID:
23025421
7.

Cost-effectiveness of adult vaccination strategies using pneumococcal conjugate vaccine compared with pneumococcal polysaccharide vaccine.

Smith KJ, Wateska AR, Nowalk MP, Raymund M, Nuorti JP, Zimmerman RK.

JAMA. 2012 Feb 22;307(8):804-12. doi: 10.1001/jama.2012.169.

8.
9.

Cost-effectiveness of 13-valent pneumococcal conjugate vaccine in Switzerland.

Blank PR, Szucs TD.

Vaccine. 2012 Jun 13;30(28):4267-75. doi: 10.1016/j.vaccine.2012.04.028.

PMID:
22521287
10.

Invasive pneumococcal disease in young children before licensure of 13-valent pneumococcal conjugate vaccine - United States, 2007.

Centers for Disease Control and Prevention (CDC)..

MMWR Morb Mortal Wkly Rep. 2010 Mar 12;59(9):253-7.

11.

Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23).

Centers for Disease Control and Prevention (CDC).; Advisory Committee on Immunization Practices..

MMWR Morb Mortal Wkly Rep. 2010 Sep 3;59(34):1102-6.

12.

Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines.

Tyo KR, Rosen MM, Zeng W, Yap M, Pwee KH, Ang LW, Shepard DS.

Vaccine. 2011 Sep 2;29(38):6686-94. doi: 10.1016/j.vaccine.2011.06.091.

PMID:
21745516
13.
14.

The cost-effectiveness of pneumococcal conjugate vaccination in Australia.

Butler JR, McIntyre P, MacIntyre CR, Gilmour R, Howarth AL, Sander B.

Vaccine. 2004 Mar 12;22(9-10):1138-49.

PMID:
15003641
15.
16.

Economic impact of 13-valent pneumococcal conjugate vaccine in Finnish adults ≥50 years with underlying chronic medical conditions.

Martikainen JA, Soini EJ, Laine J, Ahman H, Postila V, Klemets P.

J Eval Clin Pract. 2014 Aug;20(4):333-41. doi: 10.1111/jep.12131.

PMID:
24813690
17.

Cost Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccination Program in Chronic Obstructive Pulmonary Disease Patients Aged 50+ Years in Spain.

Rodríguez González-Moro JM, Menéndez R, Campins M, Lwoff N, Oyagüez I, Echave M, Rejas J, Antoñanzas F.

Clin Drug Investig. 2016 Jan;36(1):41-53. doi: 10.1007/s40261-015-0345-z.

18.

Impact of routine PCV7 (Prevenar) vaccination of infants on the clinical and economic burden of pneumococcal disease in Malaysia.

Aljunid S, Abuduxike G, Ahmed Z, Sulong S, Nur AM, Goh A.

BMC Infect Dis. 2011 Sep 21;11:248. doi: 10.1186/1471-2334-11-248.

20.

A comparative public health and budget impact analysis of pneumococcal vaccines: The French case.

Jiang Y, Gervais F, Gauthier A, Baptiste C, Martinon P, Bresse X.

Hum Vaccin Immunother. 2015;11(9):2188-97. doi: 10.1080/21645515.2015.1011957.

Items per page

Supplemental Content

Support Center